Annual EBITDA
-$5.91 M
+$1.03 M+14.81%
December 1, 2023
Summary
- As of February 7, 2025, XRTX annual EBITDA is -$5.91 million, with the most recent change of +$1.03 million (+14.81%) on December 1, 2023.
- During the last 3 years, XRTX annual EBITDA has fallen by -$4.93 million (-502.19%).
- XRTX annual EBITDA is now -19921.36% below its all-time high of -$29.50 thousand, reached on February 1, 2015.
Performance
XRTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$848.80 K
+$611.80 K+41.89%
September 1, 2024
Summary
- As of February 7, 2025, XRTX quarterly EBITDA is -$848.80 thousand, with the most recent change of +$611.80 thousand (+41.89%) on September 1, 2024.
- Over the past year, XRTX quarterly EBITDA has increased by +$110.50 thousand (+11.52%).
- XRTX quarterly EBITDA is now -2029.09% below its all-time high of $44.00 thousand, reached on December 1, 2018.
Performance
XRTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$4.33 M
+$528.00 K+10.88%
September 1, 2024
Summary
- As of February 7, 2025, XRTX TTM EBITDA is -$4.33 million, with the most recent change of +$528.00 thousand (+10.88%) on September 1, 2024.
- Over the past year, XRTX TTM EBITDA has increased by +$1.58 million (+26.77%).
- XRTX TTM EBITDA is now -73208.47% below its all-time high of -$5900.00, reached on May 1, 2014.
Performance
XRTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
XRTX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +14.8% | +11.5% | +26.8% |
| 3 y3 years | -502.2% | +53.9% | +53.0% |
| 5 y5 years | -115.4% | +53.9% | +53.0% |
XRTX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -362.3% | +14.8% | at high | +70.5% | -48.0% | +57.7% |
| 5 y | 5-year | -1247.8% | +14.8% | -6141.2% | +70.5% | -1146.5% | +57.7% |
| alltime | all time | <-9999.0% | +14.8% | -2029.1% | +70.5% | <-9999.0% | +57.7% |
XORTX Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$848.80 K(-41.9%) | -$4.33 M(-10.9%) |
| Jun 2024 | - | -$1.46 M(+38.2%) | -$4.85 M(-5.3%) |
| Mar 2024 | - | -$1.06 M(+10.1%) | -$5.12 M(-13.3%) |
| Dec 2023 | -$5.91 M(-14.8%) | -$959.30 K(-30.3%) | -$5.91 M(-22.1%) |
| Sep 2023 | - | -$1.38 M(-20.4%) | -$7.58 M(-8.5%) |
| Jun 2023 | - | -$1.73 M(-6.0%) | -$8.29 M(-9.9%) |
| Mar 2023 | - | -$1.84 M(-30.2%) | -$9.20 M(-10.1%) |
| Dec 2022 | -$6.93 M(+442.7%) | -$2.64 M(+26.7%) | -$10.23 M(+14.9%) |
| Sep 2022 | - | -$2.08 M(-21.2%) | -$8.90 M(+24.8%) |
| Jun 2022 | - | -$2.64 M(-8.0%) | -$7.13 M(+37.5%) |
| Mar 2022 | - | -$2.87 M(+119.8%) | -$5.19 M(+77.5%) |
| Dec 2021 | -$1.28 M(+30.3%) | - | - |
| Dec 2021 | - | -$1.31 M(+316.3%) | -$2.92 M(+46.4%) |
| Sep 2021 | - | -$313.90 K(-54.8%) | -$2.00 M(+0.1%) |
| Jun 2021 | - | -$694.40 K(+14.4%) | -$1.99 M(+27.2%) |
| Mar 2021 | - | -$607.00 K(+59.7%) | -$1.57 M(+60.9%) |
| Dec 2020 | -$980.80 K(+123.8%) | -$380.20 K(+21.5%) | -$974.20 K(+33.8%) |
| Sep 2020 | - | -$312.80 K(+16.9%) | -$728.20 K(+43.5%) |
| Jun 2020 | - | -$267.60 K(+1867.6%) | -$507.30 K(+46.2%) |
| Mar 2020 | - | -$13.60 K(-89.9%) | -$347.00 K(-0.2%) |
| Dec 2019 | -$438.20 K | -$134.20 K(+46.0%) | -$347.80 K(+105.1%) |
| Sep 2019 | - | -$91.90 K(-14.4%) | -$169.60 K(-45.0%) |
| Jun 2019 | - | -$107.30 K(+645.1%) | -$308.40 K(-23.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$14.40 K(-132.7%) | -$400.30 K(-85.4%) |
| Dec 2018 | -$2.74 M(+689.7%) | $44.00 K(-119.1%) | -$2.74 M(-8.7%) |
| Sep 2018 | - | -$230.70 K(+15.8%) | -$3.00 M(+4.0%) |
| Jun 2018 | - | -$199.20 K(-91.5%) | -$2.89 M(+6.0%) |
| Mar 2018 | - | -$2.35 M(+1153.7%) | -$2.72 M(+509.2%) |
| Dec 2017 | -$347.20 K(+136.7%) | -$187.70 K(+507.4%) | -$447.00 K(+72.4%) |
| Nov 2017 | - | -$30.90 K(-50.6%) | -$259.30 K(-4.4%) |
| Sep 2017 | - | -$62.60 K(+16.6%) | -$271.20 K(+30.0%) |
| Aug 2017 | - | -$53.70 K(+52.6%) | -$208.60 K(+7.1%) |
| May 2017 | - | -$35.20 K(-21.1%) | -$194.70 K(+0.7%) |
| Mar 2017 | - | -$44.60 K(+38.1%) | -$193.40 K(+30.0%) |
| Feb 2017 | -$146.70 K(-49.5%) | -$32.30 K(-24.5%) | -$148.80 K(+42.7%) |
| Dec 2016 | -$290.30 K(+92.3%) | - | - |
| Nov 2016 | - | -$42.80 K(+7.5%) | -$104.30 K(-27.1%) |
| Aug 2016 | - | -$39.80 K(+17.4%) | -$143.10 K(+3.3%) |
| May 2016 | - | -$33.90 K(-377.9%) | -$138.50 K(-10.6%) |
| Feb 2016 | -$151.00 K(+411.9%) | $12.20 K(-115.0%) | -$155.00 K(-13.7%) |
| Nov 2015 | - | -$81.60 K(+131.8%) | -$179.70 K(+73.3%) |
| Aug 2015 | - | -$35.20 K(-30.2%) | -$103.70 K(+39.0%) |
| May 2015 | - | -$50.40 K(+303.2%) | -$74.60 K(+147.8%) |
| Feb 2015 | -$29.50 K | -$12.50 K(+123.2%) | -$30.10 K(+71.0%) |
| Nov 2014 | - | -$5600.00(-8.2%) | -$17.60 K(+46.7%) |
| Aug 2014 | - | -$6100.00(+3.4%) | -$12.00 K(+103.4%) |
| May 2014 | - | -$5900.00 | -$5900.00 |
FAQ
- What is XORTX Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for XORTX Therapeutics?
- What is XORTX Therapeutics annual EBITDA year-on-year change?
- What is XORTX Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for XORTX Therapeutics?
- What is XORTX Therapeutics quarterly EBITDA year-on-year change?
- What is XORTX Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for XORTX Therapeutics?
- What is XORTX Therapeutics TTM EBITDA year-on-year change?
What is XORTX Therapeutics annual EBITDA?
The current annual EBITDA of XRTX is -$5.91 M
What is the all time high annual EBITDA for XORTX Therapeutics?
XORTX Therapeutics all-time high annual EBITDA is -$29.50 K
What is XORTX Therapeutics annual EBITDA year-on-year change?
Over the past year, XRTX annual EBITDA has changed by +$1.03 M (+14.81%)
What is XORTX Therapeutics quarterly EBITDA?
The current quarterly EBITDA of XRTX is -$848.80 K
What is the all time high quarterly EBITDA for XORTX Therapeutics?
XORTX Therapeutics all-time high quarterly EBITDA is $44.00 K
What is XORTX Therapeutics quarterly EBITDA year-on-year change?
Over the past year, XRTX quarterly EBITDA has changed by +$110.50 K (+11.52%)
What is XORTX Therapeutics TTM EBITDA?
The current TTM EBITDA of XRTX is -$4.33 M
What is the all time high TTM EBITDA for XORTX Therapeutics?
XORTX Therapeutics all-time high TTM EBITDA is -$5900.00
What is XORTX Therapeutics TTM EBITDA year-on-year change?
Over the past year, XRTX TTM EBITDA has changed by +$1.58 M (+26.77%)